Genmab — September 2020
-
GB When is the cut-off date for the Hexa cd38 option?
-
Yes they can
-
Det ville være en særdeles usædvanlig optakt til et opkøb
-
-
There are restrictions. Hexa-cd38 can not go in direct competion with DARZALEX
-
@Darvin forklar mig hvorfor de kan vinde tvisten om patent til 35 hvis de modsiger at have noget med Halo at gøre, det er alene Halo der giver patent til 35 og når patentet udløber i 2029 så må alle andre kombinere Dara med hvad som helst. De kan ikke både få i hoved og sæk, men enig i at alt kan lade sig gøre, virker bare ikke særlig sandsynligt i min optik.
-
Should Janssen not exercise its option, the terms of the agreement allow Genmab to continue to develop and commercialize HexaBody-CD38 for DARZALEX-resistant patients, and in all other indications except those multiple myeloma or amyloidosis indications where DARZALEX is either approved or is being actively developed.
-
Now we know why Jan want to develope Hexa-cd38 in B-cell lymphoma...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind